ARTICLE | Clinical News
Darzalex daratumumab regulatory update
August 8, 2016 7:00 AM UTC
FDA granted breakthrough therapy designation to Genmab’s Darzalex daratumumab in combination with Revlimid lenalidomide and dexamethasone, or with Velcade bortezomib and dexamethasone, as a second-l...